...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British journal of neurosurgery >Role of simvastatin in prevention of vasospasm and improving functional outcome after aneurysmal sub-arachnoid hemorrhage: A prospective, randomized, double-blind, placebo-controlled pilot trial
【24h】

Role of simvastatin in prevention of vasospasm and improving functional outcome after aneurysmal sub-arachnoid hemorrhage: A prospective, randomized, double-blind, placebo-controlled pilot trial

机译：辛伐他汀在预防动脉痉挛性蛛网膜下腔出血后血管痉挛和改善功能结局中的作用：一项前瞻性，随机，双盲，安慰剂对照的试验性研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. Vasospasm plays a major role in the morbidity and mortality after aneurysmal subarachnoid hemorrhage (aSAH). The preliminary studies suggest that statins protect against cerebral vasospasm. Objective. The aim of the study was to determine the role of simvastatin in preventing clinical vasospasm and improving functional outcome in patients with aSAH. Methods. All patients with aSAH admitted within 96 h of ictus were randomized to receive either Simvastatin or placebo-80 mg/day for 14 days. Thirty eight patients were recruited in the study-19 received Simvastatin and 19 placebo. All the patients underwent surgical clipping of the aneurysm. The primary outcome of the study was the development of clinical cerebral vasospasm. The secondary outcomes included Glasgow Outcome Score (GOS), Modified Rankin Scale (MRS) and Barthel Index Score (MBI) at follow-up at 1, 3 and 6 months. Results. 16% of the patients in the simvastatin group had high Middle Cerebral Artery velocities (> 160 cm/sec) on transcranial Doppler on one or more than one day during the study duration as compared to 26% of the patients in the placebo group (p = 0.70). Neurological deterioration occurred in 26% and 42% of the patients in simvastatin group versus placebo group, respectively (p = 0.31). There was an improvement in the functional outcome in the simvastatin group at 1, 3 or 6 months in the follow-up; however, this difference was not statistically significant. Conclusions. There was benefit of simvastatin in terms of reduction in clinical vasospasm, mortality or improved functional outcome, however, this was not statistically significant.
机译：背景。血管痉挛在动脉瘤性蛛网膜下腔出血（aSAH）后的发病率和死亡率中起主要作用。初步研究表明，他汀类药物可预防脑血管痉挛。目的。该研究的目的是确定辛伐他汀在预防aSAH患者的临床血管痉挛和改善功能结局中的作用。方法。所有在发作后96小时内入院的aSAH患者被随机分配接受辛伐他汀或安慰剂80 mg /天治疗14天。在研究19中招募了38名患者接受了辛伐他汀和19种安慰剂。所有患者均接受了动脉瘤的手术切除。该研究的主要结果是临床脑血管痉挛的发展。次要结果包括随访1、3、6个月时的格拉斯哥预后评分（GOS），改良Rankin量表（MRS）和巴塞尔指数评分（MBI）。结果。在研究期间，辛伐他汀组中有16％的患者在一天多于一天的经颅多普勒超声检查时出现中脑动脉流速高（> 160 cm / sec），而安慰剂组为26％（p = 0.70）。辛伐他汀组和安慰剂组分别有26％和42％的患者发生神经功能恶化（p = 0.31）。随访1、3或6个月，辛伐他汀组的功能预后有所改善;但是，这种差异在统计上并不显着。结论辛伐他汀在减少临床血管痉挛，死亡率或改善功能预后方面具有益处，但是，这在统计学上并不显着。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号